Key Takeaways:
- Granules India has received tentative USFDA approval for an amphetamine extended‑release orally disintegrating ADHD tablet.
- The approval positions the company to enter an estimated USD 172 million US market currently served by only one generic and one authorised generic.
- Manufacture will take place at Granules’ US facility in Chantilly, Virginia, strengthening its US generics portfolio.
- Granules India USFDA approval could expand patient access to a vital ADHD therapy and bolster the company’s complex dosage capabilities.
Hyderabad‑based Granules India has secured tentative approval from the US Food and Drug Administration to market a generic version of an attention‑deficit hyperactivity disorder medication in the United States, the company announced on Monday.
Granules India USFDA approval
The approval applies to Amphetamine extended‑release orally disintegrating tablets in multiple strengths, an ANDA (Abbreviated New Drug Application) filed by Granules Pharmaceuticals Inc., the company’s wholly owned US subsidiary. The product is the generic equivalent of Adzenys XR‑ODT and will be produced at Granules’ Chantilly, Virginia facility.
Granules said the tentative approval opens a pathway to supply a formulation designed for patient convenience and adherence. The medication is indicated for the treatment of ADHD, one of the most commonly diagnosed neurodevelopmental disorders in the US that affects millions of people globally.
Market analysts at IQVIA estimate the product’s addressable market at around USD 172 million. Granules noted that the current market contains only one approved generic and one authorised generic, a competitive landscape that gives the company room to capture market share upon launch.
Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, said the approval strengthens the firm’s US generics portfolio and reflects ongoing investments in complex dosage forms and patient‑friendly delivery technologies. He added that the company remains focused on delivering value‑driven healthcare solutions.
Manufacturing the tablets at the Chantilly facility will allow Granules to supply the US market directly, reducing logistical complexity and helping to meet regulatory standards. The company has in recent years invested in expanding its capabilities for specialised and controlled‑release formulations, an area that typically demands higher regulatory scrutiny and technical expertise.
Industry observers said the tentative approval is a meaningful step. While tentative status can delay commercial launch until exclusivity or patent issues are resolved, it nevertheless signals regulatory acceptance of the product’s quality, safety and bioequivalence to the reference medicine.
For patients and payers, increased competition in the ADHD drug market can translate into better access and lower costs. ADHD remains a significant public health concern in the US and beyond, and generics play a central role in widening treatment options.
For Granules India, the development complements a broader strategy of building a robust portfolio of US‑approved generics and expanding its footprint in developed markets. Success with this product would add a commercially relevant asset and could support further investments in controlled‑release and patient‑friendly formats.
The company did not provide an exact commercial launch date, which will depend on final regulatory clearances and market conditions. Investors and market watchers will be closely following subsequent regulatory updates and any exclusivity timelines that could affect the product’s entry into the market.
Granules’ latest approval underscores the growing role of Indian pharmaceutical firms in supplying affordable medicines to global markets, while also highlighting the technical and regulatory capabilities required to manufacture complex dosage forms for patients in the US.
